Diabetic kidney disease: Act now or pay later

Pediatric Nephrology

Volumn 25, Issue 2, 2010, Pages 181-184

  Atkins, Robert C ^a   Zimmet, Paul ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

DEVELOPING COUNTRY; DIABETES CONTROL; DIABETIC NEPHROPATHY; EARLY DIAGNOSIS; EDITORIAL; GEOGRAPHIC DISTRIBUTION; GLYCEMIC CONTROL; HEALTH PROMOTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MEDICAL INFORMATION; MICROALBUMINURIA; NATIONAL HEALTH ORGANIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RISK ASSESSMENT; SCREENING TEST; CHRONIC KIDNEY FAILURE; DISEASE COURSE; EPIDEMIC; HEALTH; SECONDARY PREVENTION;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE OUTBREAKS; DISEASE PROGRESSION; HUMANS; KIDNEY FAILURE, CHRONIC; SECONDARY PREVENTION; WORLD HEALTH;

EID: 77950508665     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-009-1400-x     Document Type: Editorial

References (29)

1. International Diabetes Federation and International Society of Nephrology (2003) Diabetes and Kidney Disease: Time to Act. International Diabetes Federation, Brussels
2. Zimmet P, Alberti K, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782-787 (Pubitemid 34000780)
3. King H, Aubert R, Herman W (1998) Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431 (Pubitemid 28405191)
4. Yoon K, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY (2006) Epidemic obesity and type 2 diabetes in Asia. Lancet 368:1681-1688 (Pubitemid 46048556)
5. Sicree R, Shaw J, Zimmet P (2006) Diabetes and impaired glucose tolerance. In: Gan D (ed) Diabetes Atlas, 3rd edn. International Diabetes Federation, Brussels, pp 15-109
6. Reutens AT, Prentice L, Atkins R (2008) The epidemiology of diabetic kidney disease. In: Ekoé J, RewersM,Williams R, Zimmet P (eds) The epidemiology of diabetes mellitus, 2nd edn. JohnWiley & Sons, Chichester, pp 499-518
7. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (2007) International comparisons, in 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, Maryland, USA, pp 239-254
8. McDonald S, Excell L, Livingston B (eds) (2008) Appendix II, in ANZDATA registry report, Australia and New Zealand dialysis and transplant registry. Adelaide, pp 1-97
9. Yamagata K, Iseki K, Nitta K, Imai H, Iino Y, Matsuo S, Makino H, Hishida A (2008) Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 12:1-8
10. Lysaght M (2002) Maintenance dialysis population dynamics: Current trends and long term implications. J Am Soc Nephrol 13: S37-S40
11. Adler A, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS GROUP (2003) Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225-232 (Pubitemid 35463925)
12. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, UKPDS Study Group (2006) Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 55:1832-1839
13. Parving H, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG, DEMAND investigators (2006) Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. Kidney Int 69:2057-2063 (Pubitemid 43924271)
14. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J, ADVANCE Collaborative Group (2009) Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20:1813-1821
15. Dunstan D, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE (2002) The rising prevalence of diabetes and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 25:829-834
16. White S, Polkinghorne KR, Cass A, Shaw J, Atkins RC, Chadban SJ (2008) Limited knowledge of kidney disease in a survey of AusDiab study participants. Med J Aust 188:204-208
17. Whaley-Connell A, Sowers JR, McCullough PA, Roberts T, McFarlane SI, Chen SC, Li S, Wang C, Collins AJ, Bakris GL, KEEP Investigators (2008) Diabetes mellitus and CKD awareness: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 53[Suppl 4]:S11-21 (Pubitemid 351417308)
18. Thomas M, Viberti G, Groop P (2008) Screening for chronic kidney disease in patients with diabetes: Are we missing the point? Nat Clin Pract Nephrol 4:2-3 (Pubitemid 350308224)
19. Holman R, Paul SK, Bethel MA, Matthews DR, Neil HA (2008)
20. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589
21. Bilous R (2008) Microvascular disease: What does the UKPDS tell us about diabetic nephropathy? Diabet Med 25[Suppl 2]: 25-29 (Pubitemid 352020092)
22. Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580-591 (Pubitemid 351214285)
23. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B, ADVANCE Collaborative Group (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 370:829-840 (Pubitemid 47362321)
24. The Advance Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572 (Pubitemid 351831357)
25. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A, Woodward M, Chalmers J, ADVANCE Collaborative Group, Cass A, Glasziou P, Harrap S, Lisheng L, Mancia G, Pillai A, Poulter N, Perkovic V, Travert F (2009) Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE. Diabetes Care 32:2068-2074
26. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G, Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941-1951 (Pubitemid 39447135)
27. Parving H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878 (Pubitemid 32397855)
28. Lewis E, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:8518-8560
29. Burney B, Kalaitzidis R, Bakris G (2009) Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens 18:107-111